Non Small Cell Lung Cancer Stage III Met - IV 2nd Line

Stanford Cancer Center
Thoracic CRG
Click here to print
this page (PDF)
1 July 2015
Non Small Cell Lung Cancer (NSCLC)
Stage III Met - IV 2nd Line
Failed Therapy
LUN0044
Phase I Erlotinib
and Dovitinib
(TKI258) in
Advanced Nonsmall Cell Lung
Cancer (NSCLC)
PI: Wakelee
Stanford
EGFR
Mutation;
Failed TK1
PD-L1
Positive
LUN0063
Phase 1
MEDI4736 in
Advanced
Solid Tumors
PI: Wakelee
MedImmune
1st Priority
ECOGS1400
Phase II/III
Biomarker in
Second Line
Therapy of
Squamous Cell
Lung Cancer
(Screening Step)
LUN0069
Phase III Oral
Rociletinib
Monotherapy vs
Cytotoxic
Chemotherapy
in Mutant EGFR
NSCLC
PI: Wakelee
Pending
PI: Wakelee
Pending
2nd Priority
Metastatic
Brain
ALK +
VAR0098
Phase I First-inHuman DoseEscalation/
Safety/
Tolerability/
Pharmacokinetic
s of X-396 in
Solid Tumors
PI: Wakelee
Xcovery
Metastatic
Brain
METS0002
Phase II Oral
Ceritinib Tx in
ALK-Positive
NSCLC
Metastatic to the
Brain and/or to
Leptomeninges
PI: Neal
Pending
LUN0067
Phase 2
Etirinotecan Pegol
(NKTR-102) in
Adv. Lung Cancer
and Refractory
Brain Mets
PI: Neal
Stanford
On Gefitinib
VAR0069
IRESSA™Gefi
tinib for
Continued Tx
of Patients
Who Are
Benefiting /
Have
Benefited from
Gefitinib Tx
PI: Wakelee
AstraZeneca
KEY
Pending
Open for Enrollment
Observational Study
Optional Path
Link
Extension Study
Trial Posting
Enrollment on Hold
Please mark up a copy using black ink and fax changes to 725-9204